Sugi Predict

Sugi Predict / Compounds / SCHEMBL4985915

SCHEMBL4985915

SCHEMBL4985915

CCOC(=O)CC(=O)COCCN1C(=O)c2ccccc2C1=O

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.50
▸ POLB P06746 2/20 0.50
▸ APEX1 P27695 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ GAA P10253 3/20 0.48
▸ MAPT P10636 1/20 0.47
▸ TSHR P16473 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ HPGD P15428 3/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9760318 0.97 HSD17B10 (0.48) HSD17B10POLBAPEX1TDP1L3MBTL1
SCHEMBL9760700 0.90 ALDH1A1 (0.47) HSD17B10POLBAPEX1TDP1L3MBTL1
SCHEMBL4983346 0.88 HSD17B10 (0.53) HSD17B10POLBAPEX1TDP1ALDH1A1
SCHEMBL9761285 0.88 TSHR (0.48) HSD17B10POLBAPEX1TDP1L3MBTL1
SCHEMBL8892737 0.87 POLB (0.55) HSD17B10POLBAPEX1TDP1ALDH1A1
SCHEMBL9760740 0.84 HSD17B10 (0.46) HSD17B10POLBAPEX1TDP1L3MBTL1
SCHEMBL5050634 0.84 NPSR1 (0.61) HSD17B10POLBAPEX1TDP1L3MBTL1
SCHEMBL10766778 0.84 SMN1; SMN2 (0.46) HSD17B10POLBAPEX1TDP1L3MBTL1
SCHEMBL7272170 0.84 SMN1; SMN2 (0.46) HSD17B10POLBAPEX1TDP1L3MBTL1
SCHEMBL10561030 0.84 POLB (0.55) POLBALDH1A1SMN1; SMN2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119735577-A Amlodipine Process for the preparation of intermediates 珠海润都制药股份有限公司 2025-04-01 — — CN claimed
CN-115536577-B Preparation method of amlodipine alkali 浙江昂利康制药股份有限公司 2024-04-30 — — CN claimed
CN-115536577-A Preparation method of amlodipine alkali 浙江昂利康制药股份有限公司 2022-12-30 — — CN claimed
CN-112162047-B Method for determining content of genotoxic impurities in amlodipine besylate 宁波大红鹰药业股份有限公司 2022-08-02 — — CN claimed
CN-112162047-A Method for determining content of genotoxic impurities in amlodipine besylate 宁波大红鹰药业股份有限公司 2021-01-01 — — CN claimed
US-6784297-B2 CONDENSING PHTHALIC ANHYDRIDE AND ETHANOLAMINE, COUPLING WITH ETHYL 4-CHLORACETOACETATE/O-CHLOROBENZALDEHYDE, CONDENSING (CYCLIZATION) WITH METHYL AMINOCROTONATE, PURIFYING, HYDROLYZING, SALT FORMING; COMMERCIALLY VIABLE; EFFICIENCY KOPRAN LIMITED (IN) 2004-08-31 — — US claimed
US-20040044218-A1 Reacting phthalic anhydride with ethanolamine KOPRAN LIMITED (IN) 2004-03-04 — — US claimed
CN-119735577-A Amlodipine Process for the preparation of intermediates 珠海润都制药股份有限公司 2025-04-01 — — CN disclosed
CN-115536577-B Preparation method of amlodipine alkali 浙江昂利康制药股份有限公司 2024-04-30 — — CN disclosed
CN-112162047-B Method for determining content of genotoxic impurities in amlodipine besylate 宁波大红鹰药业股份有限公司 2022-08-02 — — CN disclosed
CN-112162047-A Method for determining content of genotoxic impurities in amlodipine besylate 宁波大红鹰药业股份有限公司 2021-01-01 — — CN disclosed
US-20080070789-A1 PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR SLANINA PAVEL 2008-03-20 — — US disclosed
US-20080070789-A1 PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR SLANINA PAVEL 2008-03-20 — — US disclosed
EP-0225175-A2 Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof FISONS plc (GB) 1987-06-10 — — EP disclosed
US-4670449-A HYPOTENSIVE AGENTS PFIZER INC. (US) 1987-06-02 — — US disclosed
US-4661485-A 2-pyrimidylaminoalkoxymethyl-6-methyl-3,5-bis (alkoxycarbony-1)-1,4-dihydropyridine antihypertensive agents PFIZER INC. (US) 1987-04-28 — — US disclosed
US-4572909-A 2-(Secondary aminoalkoxymethyl) dihydropyridine derivatives as anti-ischaemic and antihypertensive agents PFIZER INC. (US) 1986-02-25 — — US disclosed
US-4572908-A HYPOTENSIVE AND ANTIISCHEMIC AGENTS PFIZER INC. (US) 1986-02-25 — — US disclosed
EP-0116769-A1 Dihydropyridines Pfizer Limited (GB) 1984-08-29 — — EP disclosed
EP-0089167-A2 Dihydropyridine anti-ischaemic and antihypertensive agents, processes for their production, and pharmaceutical compositions containing them Pfizer Limited (GB) 1983-09-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044218-A1 Reacting phthalic anhydride with ethanolamine H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA2, H1-4 HSD17B10 1985/4885POLB 2370/4885APEX1 3453/4885
US-20080070789-A1 PROCESS FOR MAKING AMLODIPINE, DERIVATIVES THEREOF, AND PRECURSORS THEREFOR CACNA1D, CACNA1F, CYP51A1 HSD17B10 489/4885POLB 3828/4885APEX1 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.